Whole-of-population CRISPR point-of-care testing for congenital cytomegalovirus to prevent hearing and neurodevelopment disabilities through a public health approach [ 7/1/2021 - 6/30/2026 ]

Research Grant

Brief description Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.

Funding Amount $2,058,921

Funding Scheme Clinical Trials and Cohort Studies Grants

Chief Investigator A/Pr Valerie Sung

Notes Clinical Trials and Cohort Studies Grants